ClinicalTrials.gg
Active, not recruitingNCT05382442Updated Oct 14, 2025

A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer

A Phase 2 interventional study of AK112 and AK117 in Metastatic Colorectal Cancer, sponsored by Akeso. Active, not recruiting at 4 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-10-14.

Sponsored by Akeso · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
254
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,339 studies in Colorectal Neoplasms with a site in United States — 418 open to participants now, 630 under way, 30 of them phase 3. Colorectal Neoplasms · United States.

Planned enrollment
466th of 1,932
254 · median 64
Started
2022
with 126 others
Phase 2
510 of 2,339
65 open now
Primary completion
2026-05
later than 88 of 628 live
Registered
1,762nd of 2,339
by date

Among the 2,339 studies in Colorectal Neoplasms with a site in United States, this one is the 466th largest by planned enrollment of the 1,932 interventional ones that give a count, is one of 127 that started in 2022, is one of 510 in phase 2, reaches primary completion later than 88 of the 628 other live ones, and was the 1,762nd registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

418 of the 2,339 studies in Colorectal Neoplasms with a site in United States are open now. Recruiting first, the newest first:

413 more — sign in →

All 418 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,339 studies in Colorectal Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This trial is a Phase II study. The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of AK112 with or without AK117 in participants with metastatic colorectal cancer who are not suitable for surgery.

03

Conditions studied

  • Metastatic Colorectal Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proven diagnosis of colorectal adenocarcinoma
  • Part1: Subjects who have not previously received any systemic antitumor therapy and who have previously received or adjuvant therapy, the first detection of recurrence or should be ≥12 months after the last administration of neoadjuvant or adjuvant therapy
  • Part2: Subjects who have previously received systemic therapy including fluorouracil, oxaliplatin, irinotecan, bevacizumab or anti-EGFR antibodies or could not tolerate or have to standard treatment
  • performance status of 0 or 1
  • as defined by v1.1
  • Adequate hematologic and organ function

Exclusion criteria

Exclusion Criteria:

  • Known MSI-H(Microsatellite-Instability-High) or dMMR(Mismatch Repair-Deficient)
  • Prior treatment with immunotherapy, including , immune checkpoint agonists, immune cell therapy and any treatment targeting tumor immune pathway
  • History of disease
  • Prior allogeneic stem cell or solid organ transplantation
  • Positive test for ,Active or
  • Receipt of a live, attenuated vaccine within 30 days prior to randomization, during treatment
  • Pregnancy or lactation
  • Dysphagia
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
254 participants (estimated)

Study arms

  • Experimental
    Part 1_Chemotherapy Regimen Selection Stage Group A(AK112+AK117+XELOX)

    AK112+AK117+XELOX AK112 and AK117 and XELOX(Oxaliplatin 130 mg/sqm iv day 1, Capecitabine via oral, the total daily dose was 2000mg/sqm, day1-14) If no progression occurs during AK112 plus AK117 plus XELOX, patients will receive maintenance capecitabine plus AK112 plus AK117 at the same dose used at the last cycle of the induction treatment. Capecitabine plus AK112 plus AK117 will be repeated every 3 weeks until disease progression, unacceptable toxicity or patient's refusal.

    Drug: AK112 · Drug: AK117 · Drug: Oxaliplatin · Drug: Capecitabine

  • Experimental
    Part 1_Chemotherapy Regimen Selection Stage Group B(AK112+AK117+FOLFOXIRI)

    AK112+AK117+FOLFOXIRI AK112 and AK117 and FOLFOXIRI(Irinotecan 150-165 mg/sqm iv day 1, Oxaliplatin 85 mg/sqm iv day 1, Leucovorin(LV) 400 mg/sqm iv day 1, 5-fluorouracil(5-FU) 2400-2800 mg/sqm 46-48 hours continuous infusion, starting on day 1) If no progression occurs during AK112 plus AK117 plus FOLFOXIRI, patients will receive maintenance 5-FU/LV plus AK112 plus AK117 at the same dose used at the last cycle of the induction treatment. 5-FU/LV plus AK112 plus AK117 will be repeated biweekly until disease progression, unacceptable toxicity or patient's refusal.

    Drug: AK112 · Drug: AK117 · Drug: Oxaliplatin · Drug: Irinotecan · Drug: Leucovorin · Drug: 5-fluorouracil

  • Experimental
    Part 1_Expansion Stage Group A(AK112 DS1+Chemotherapy)

    AK112 (Dose1) +Chemotherapy(Decided by Chemotherapy Regimen Selection Stage) AK112 and XELOX or FOLFOXIRI(the same dosage, frequency and duration with Chemotherapy Regimen Selection Stage)

    Drug: AK112 · Drug: Oxaliplatin · Drug: Capecitabine · Drug: Irinotecan · Drug: Leucovorin · Drug: 5-fluorouracil

  • Experimental
    Part 1_Expansion Stage Group B(AK112 DS1+AK117 DS1+Chemotherapy)

    AK112 (Dose1) +AK117 (Dose1) +Chemotherapy(Decided by Chemotherapy Regimen Selection Stage) AK112 and AK117 and XELOX or FOLFOXIRI(the same dosage, frequency and duration with Chemotherapy Regimen Selection Stage)

    Drug: AK112 · Drug: AK117 · Drug: Oxaliplatin · Drug: Capecitabine · Drug: Irinotecan · Drug: Leucovorin · Drug: 5-fluorouracil

  • Experimental
    Part 1_Expansion Stage Group C (AK112 DS2+Chemotherapy)

    AK112 (Dose2)+Chemotherapy(Decided by Chemotherapy Regimen Selection Stage). AK112 and XELOX or FOLFOXIRI(the same dosage, frequency and duration with Chemotherapy Regimen Selection Stage).

    Drug: AK112 · Drug: Oxaliplatin · Drug: Capecitabine · Drug: Irinotecan · Drug: Leucovorin · Drug: 5-fluorouracil

  • Experimental
    Part 1_Expansion Stage Group D (AK112 DS2 +AK117 DS2 +Chemotherapy)

    AK112(Dose2) + AK117(Dose2)+Chemotherapy(Decided by Chemotherapy Regimen Selection Stage) AK112 and AK117 and XELOX or FOLFOXIRI(the same dosage, frequency and duration with Chemotherapy Regimen Selection Stage)

    Drug: AK112 · Drug: AK117 · Drug: Oxaliplatin · Drug: Capecitabine · Drug: Irinotecan · Drug: Leucovorin · Drug: 5-fluorouracil

  • Experimental
    Part 1_Expansion Stage Group E (AK112 DS2+AK117 DS1+Chemotherapy)

    AK112(Dose2)+AK117(Dose1)+Chemotherapy(Decided by Chemotherapy Regimen Selection Stage) AK112 and AK117 and XELOX or FOLFOXIRI(the same dosage, frequency and duration with Chemotherapy Regimen Selection Stage)

    Drug: AK112 · Drug: AK117 · Drug: Oxaliplatin · Drug: Capecitabine · Drug: Irinotecan · Drug: Leucovorin · Drug: 5-fluorouracil

  • Experimental
    Part 1_Extension Stage Group F (AK112 DS1 + mFOLFOX6)

    AK112 (Dose1) +mFOLFOX6 ( Oxaliplatin 85 mg/sqm IV day 1, Leucovorin 400 mg/sqm IV day 1, 5-fluorouracil(5-FU) 2400 mg/sqm 46-48 hours continuous infusion, starting on day 1). If no progression occurs during AK112 plus mFOLFOX6, patients will receive maintenance 5- FU/LV plus AK112 at the same dose used at the last cycle of the induction treatment. 5-FU/LV plus AK112 will be repeated biweekly until disease progression, unacceptable toxicity or patient's refusal.

    Drug: AK112 · Drug: Oxaliplatin · Drug: Leucovorin · Drug: 5-fluorouracil

  • Experimental
    Part 1_Extension Stage Group G (AK112 DS2+mFOLFOX6)

    AK112 (Dose2) +mFOLFOX6 ( Oxaliplatin 85 mg/sqm IV day 1, Leucovorin 400 mg/sqm IV day 1, 5-fluorouracil(5-FU) 2400 mg/sqm 46-48 hours continuous infusion, starting on day 1) If no progression occurs during AK112 plus mFOLFOX6, patients will receive maintenance 5- FU/LV plus AK112 at the same dose used at the last cycle of the induction treatment. 5-FU/LV plus AK112 will be repeated biweekly until disease progression, unacceptable toxicity or patient's refusal.

    Drug: AK112 · Drug: Oxaliplatin · Drug: Leucovorin · Drug: 5-fluorouracil

  • Experimental
    Part 2 cohort 1(AK112)

    Subjects receive AK112 until disease progression or unacceptable toxicity AK112 (until disease progression, unacceptable toxicity or patient's refusal)

    Drug: AK112

  • Experimental
    Part 2 cohort 2(AK112+AK117)

    Subjects receive AK117 and AK112 until disease progression or unacceptable toxicity AK112 and AK117 ( until disease progression, unacceptable toxicity or patient's refusal)

    Drug: AK112 · Drug: AK117

Interventions

  • DrugAK112

    AK112 via intravenous (IV) infusion until disease progression or unacceptable toxicity

  • DrugAK117

    AK117 via intravenous (IV) infusion until disease progression or unacceptable toxicity

  • Oxaliplatin via IV infusion

  • Capecitabine via oral,The total daily dose was 2000mg/sqm, Each cycle was administered for 2 consecutive weeks, followed by a week of rest, with a treatment cycle every 21 days

  • Irinotecan via IV infusion

  • Leucovorin via IV infusion

  • 5-fluorouracil via IV infusion

06

What researchers measure

Primary outcomes

  1. Objective response rates (ORR)

    ORR is the proportion of subjects with complete response(CR) or partial response(PR) , based on RECIST v1.1

    Time frame: Up to approximately 2 years

  2. Number of participants with adverse events (AEs)

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Disease control rate (DCR)

    Disease control rate (DCR) is defined as the proportion of subjects with CR, PR, or stable disease(SD) based on RECIST V1.1

    Time frame: Up to approximately 2 years

  2. Duration of response (DOR)

    DOR is defined for participants who had an objective response as the time from the first occurrence of a documented confirmed response (CR or PR) to the date of disease progression per RECIST v1.1 or death from any cause,whichever occurred first

    Time frame: Up to approximately 2 years

  3. Time to response (TTR)

    TTR is defined for participants who had an objective response as the time from the start of treatment to the first occurrence of a documented unconfirmed response (CR or PR) .

    Time frame: Up to approximately 2 years

  4. Progression-free survival (PFS)

    PFS is defined as the time from the start of treatment till the first documentation of disease progression (per RECIST v1.1 criteria) assessed by the investigator or death due to any cause (whichever occurs first).

    Time frame: Up to approximately 2 years

  5. Progression-free survival 2 (PFS2)

    PFS 2 is defined as the time from the start of treatment till the second documentation of disease progression (per RECIST v1.1 criteria) assessed by the investigator or death due to any cause (whichever occurs first).

    Time frame: Up to approximately 2 years

  6. Overall survival (OS)

    Overall survival is defined as the time from the start of treatment until death due to any cause.

    Time frame: Up to approximately 2 years

07

Study locations

4 sites
  • Summit Therapeutics Research Site
    Los Angeles, California 90067, United States
  • Summit Therapeutics Research Site
    Murrieta, California 92562, United States
  • Summit Therapeutics Research Site
    Fairfax, Virginia 22031, United States
  • The Sixth Hospital,Sun Yat-sen University
    Guanzhou, Guangdong 510000, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2022 (actual). Primary completion is estimated for May 2026, 46 months after the start.

Of 120 industry-sponsored phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 72. This study's planned 46 months is above that.

Counting every sponsor, half of 618 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2022
First posted
May 19, 2022
StartActual
Jun 27, 2022
Primary completionEst.
May 15, 2026
CompletionEst.
Aug 12, 2028
Last update
Oct 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05382442
Lead sponsor
Akeso
Collaborators
Summit Therapeutics
Responsible party
Sponsor
First posted
May 19, 2022
Start date
Jun 27, 2022
Primary completion
May 15, 2026 (estimated)
Completion
Aug 12, 2028 (estimated)
Last update
Oct 14, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivonescimab

Start the discussion